Drotrecogin alfa (activated)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Drotrecogin alfa (activated)
Drotrecogin alfa (activated) is a approved stage product being developed by Eli Lilly for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00045760. Target conditions include Sepsis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00386425 | Phase 2 | Completed |
| NCT00279214 | Approved | Completed |
| NCT00067730 | Approved | Completed |
| NCT00568893 | Approved | Completed |
| NCT00045760 | Approved | Completed |
Competing Products
20 competing products in Sepsis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alkaline Phosphatase + Placebo | AM-Pharma | Phase 2 | 44 |
| Drotrecogin alfa (activated) | Eli Lilly | Phase 2 | 52 |
| Meropenem | Pfizer | Approved | 84 |
| Imipenem | Merck | Approved | 85 |
| Cefiderocol | Shionogi | Phase 1 | 33 |
| eritoran tetrasodium + Placebo | Eisai | Phase 3 | 77 |
| E5564 | Eisai | Phase 2 | 52 |
| Drotrecogin Alfa (Activated) + placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin Alfa (activated) | Eli Lilly | Approved | 85 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 77 |
| sPLA2 Inhibitor | Eli Lilly | Phase 1/2 | 41 |
| Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin | Eli Lilly | Approved | 85 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 85 |
| AZD9773 (CytoFab) | AstraZeneca | Phase 2 | 52 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD4144 + Placebo | AstraZeneca | Phase 2 | 52 |